Cardioprotective Effects of Iloprost
It is difficult on the basis of the evidence of the studies presented by Schrör, Lucchesi, Müller et al., de Langen et al., and Numano at the symposium, and others already published, to escape the conclusion, that Iloprost has a beneficial cardioprotective effect under conditions of experimental myocardial ischemia. This evidence comes from a variety of species (cats, dogs, rats, pigs), from both in vitro (isolated heart) and in vivo studies in conscious and anesthetized animals, from a variety of models of myocardial ischemia (mechanical occlusion of a major coronary artery, coronary microembolization) in which either coronary occlusion is maintained or in which reperfusion of the ischemic area is allowed to occur, and from studies in which Iloprost is given early (pre-occlusion) or late in the ischemic period. This convincing evidence is based on histology, enzyme release, various metabolic indices of ischemia and from effects on both ischemia and reperfusion-induced ventricular arrhythmias.
KeywordsIschemia Prostaglandin Noradrenaline Dial Prostacyclin
Unable to display preview. Download preview PDF.
- 3.Arnold G, Thiemermann C, Heymans L, Schrör K (1985) Morphological analysis of the Iloprost effects on reperfused ischemic myocardium. In: Schrör (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Karger, Basel, pp 254–258Google Scholar
- 5.Parratt JR (1982) Drug-induced changes in myocardial blood flow following acute coronary artery ligation. In: Tillmanns H, Kübler W, Zebee (eds) Microcirculation of the heart. Springer, Berlin, Heidelberg, New York, pp 313–324Google Scholar